OncoMed in brief
OncoMed is an unlisted company in the Biotechnology industry, based in Redwood City, USA. It was founded in 2004. In the year to December 2018 it had sales of $44 M and a net loss of $8 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About OncoMed
OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
OncoMed timeline
- 2004
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- 🔔Initial public offeringFinal prospectus filed with the SEC on 18 July 2013; shares registered for exchange trading on 8 July 2013.
Events of OncoMed from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about OncoMed
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 23 April 2019 (Form 8-K).
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -18.2%
- Operating margin
- -22.6%
- Return on equity
- -16.8%
- Liabilities / assets
- 25.9%
- Revenue growth
- +16.4%
- R&D / revenue
- 77.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2018 | $44M | +16.4% | $-10M | $-8M | -18.2% |
| Dec 2017 | $38M | +51.7% | $-41M | $-39M | -102.4% |
| Dec 2016 | $25M | -2.9% | $-103M | $-103M | -409.9% |
| Dec 2015 | $26M | -34.5% | $-86M | $-85M | -329.8% |
| Dec 2014 | $40M | +4.7% | $-51M | $-50M | -126.4% |
| Dec 2013 | $38M | +53.1% | $-24M | $-26M | -69.0% |
| Dec 2012 | $25M | -21.4% | $-22M | $-22M | -90.1% |
| Dec 2011 | $31M | — | $-15M | $-15M | -47.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2018 | $-45M | $1M | $-46M | $-0.21 | — |
| Dec 2017 | $-85M | $1M | $-86M | $-1.04 | — |
| Dec 2016 | $-37M | $1M | $-38M | $-3.14 | — |
| Dec 2015 | $-75M | $1M | $-77M | $-2.84 | — |
| Dec 2014 | $-85M | $2M | $-86M | $-1.69 | $0.00 |
| Dec 2013 | $145M | $1M | $144M | $-1.93 | $0.00 |
| Dec 2012 | $-33M | $1M | $-34M | $-21.30 | — |
| Dec 2011 | $-11M | $2M | $-14M | $-15.40 | — |
SEC filings
- Apr 23, 20198-KCurrent reportAcquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended
- Apr 17, 20198-KCurrent reportShareholder vote · Other events
- Mar 15, 20198-KCurrent reportMaterial agreement · Other events
- Mar 7, 201910-KAnnual report · period to Dec 2018
- Mar 7, 20198-KCurrent reportResults of operations
- Jan 28, 20198-KCurrent reportListing notice
- Dec 6, 20188-KCurrent reportMaterial agreement · Restructuring costs · Directors or officers changed · Regulation FD disclosure · Other events
- Nov 1, 201810-QQuarterly report · period to Sep 2018
- Nov 1, 20188-KCurrent reportResults of operations
- Oct 17, 20188-KCurrent reportOther events
- Oct 1, 20188-KCurrent reportDirectors or officers changed
- Sep 20, 20188-KCurrent reportOther events
Official filings of OncoMed with the US Securities and Exchange Commission.
Annual results
- Revenue
- $44 M
- Operating income
- $-10 M
- Net income
- $-8 M
For year ending December-2018 · source: SEC filing
Balance sheet
- Total assets
- $65 M
- Total liabilities
- $17 M
- Total equity
- $48 M
As of December-2018
Insider trading at OncoMed#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jonathan D. RootDirector | Tender in a change of control | -121,020 | — | — | 0 | Form 4 |
| filed | Alicia J. HagerSVP and General Counsel | Tender in a change of control | -39,488 | — | — | 0 | Form 4 |
| filed | Perry A. KarsenDirector | Tender in a change of control | -80,500 | — | — | 0 | Form 4 |
| filed | Yvonne LiSee Remarks | Tender in a change of control | -65,895 | — | — | 0 | Form 4 |
| filed | Deepika PakianathanDirector | Tender in a change of controlindirect | -1.99 M | — | — | 0 | Form 4 |
| filed | John A. LewickiPresident and CEO, Director | Tender in a change of control | -142,534 | — | — | 0 | Form 4 |
| filed | Robert StaggSee Remarks | Tender in a change of control | -28,917 | — | — | 0 | Form 4 |
| filed | Jack W. LasersohnDirector | Tender in a change of control | -185,709 | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
OncoMed scorecard#
Passes 7 of the 12 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (2 of 4). Fiscal year 2018.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 6
- ✓Revenue grew in the newest year16.4%Revenue up 16.4% in fiscal 2018.
- ✓Revenue up more than 5% a year over three years19.7%19.7% a year over the three years to fiscal 2018.
- ✓Faster growth over three years than its peers' median19.7%19.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.21 vs -1.04Diluted EPS -0.21 in fiscal 2018 against -1.04 the year before (report's currency).
- ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2018 against -$26 M in 2013.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2018.
Profitability2 of 4
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2018.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2018.
- ✓Operating margin above its peers' median-22.6%-22.6% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-22.6%-22.6% in fiscal 2018 against -330.3% in 2015.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities5.0×Current ratio 5.04 at the end of fiscal 2018.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2018.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
OncoMed: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 | FY 2011to Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 44+16.4%100% | 38+51.7%100% | 25−2.9%100% | 26−34.5%100% | 40+4.7%100% | 38+53.1%100% | 25−21.4%100% | 31—100% | |
| Research and development | 34−42.4%77.5% | 60−45.5%157% | 110+18.1%436% | 93+21.5%359% | 76+52.7%193% | 50+25.5%132% | 40−0.4%162% | 40—128% | |
| General and administrative | 18+8.4%40.9% | 17−11.0%43.9% | 19+1.3%74.8% | 19+35.1%71.8% | 14+18.3%34.8% | 12+62.5%30.8% | 7.2+8.6%29.0% | 6.6—21.0% | |
| Operating expenses | 54−31.2%123% | 79−38.4%207% | 129+15.3%511% | 111+23.6%430% | 90+46.2%228% | 62+31.1%163% | 47+0.9%191% | 47—149% | |
| Operating income | −10—−22.6% | −41—−107% | −103—−411% | −86—−330% | −51—−128% | −24—−63.3% | −22—−90.6% | −15—−48.5% | |
| Interest expense and finance costs | — | — | — | — | — | — | 0.0−84.2%0.0% | 0.0—0.1% | |
| Income before tax | −8.5—−19.1% | −40—−105% | −103—−410% | −85—−330% | −51—−128% | −24—−63.9% | −22—−90.1% | −15—−47.9% | |
| Income tax | −0.4—−0.9% | −1.1−7836%−2.8% | 0.0−30.0%0.1% | 0.0—0.1% | −0.5−126%−1.3% | 1.9—5.1% | 0—0.0% | — | |
| Net income including minority interests | −8.1—−18.2% | −39—−102% | −103—−410% | — | — | — | — | — | |
| Net income attributable to shareholders | −8.1—−18.2% | −39—−102% | −103—−410% | −85—−330% | −50—−126% | −26—−69.0% | −22—−90.1% | −15—−47.9% | |
| Earnings per share, basic | -0.21—— | -1.04—— | -3.14—— | -2.84—— | -1.69—— | -1.93—— | -21.30—— | -15.40—— | |
| Earnings per share, diluted | -0.21—— | -1.04—— | -3.14—— | -2.84—— | -1.69—— | -1.93—— | -21.30—— | -15.40—— | |
| Shares, weighted average (diluted) | 38+2.2%— | 38+14.5%— | 33+9.4%— | 30+1.2%— | 30+119%— | 14+1196%— | 1.0+6.9%— | 1.0—— | |
| Dividends per share | — | — | — | — | 0.00—— | 0.00—— | — | — | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 9.7−27.0%14.9% | 13−64.1%12.0% | 37−3.9%18.9% | 38+36.6%16.2% | 28−86.5%11.4% | 209+1185%62.6% | 16+38.0%20.4% | 12—— | |
| Short-term investments | 48−46.9%73.2% | 90−39.2%81.4% | 148+24.2%75.5% | 119−41.7%50.0% | 204+90.0%82.2% | 107+115%32.1% | 50—62.7% | — | |
| Receivables | — | — | — | — | — | 0—0.0% | — | — | |
| Other current assets | 1.9+11.9%2.9% | 1.7−31.5%1.5% | 2.5−23.9%1.3% | 3.3+92.8%1.4% | 1.7r1.7−32.7%0.7% | 2.5+125%0.8% | 1.1—1.4% | — | |
| Current assets | 64−39.4%97.9% | 105−44.5%95.4% | 190−18.0%97.0% | 231−4.0%97.2% | 241−24.5%97.2% | 319+347%95.5% | 71—89.5% | — | |
| Property, plant and equipment | 0.6−81.0%1.0% | 3.3−26.8%3.0% | 4.5−7.3%2.3% | 4.8−5.5%2.0% | 5.1+10.0%2.1% | 4.6−15.0%1.4% | 5.5—6.8% | — | |
| Total assets | 65−41.0%100% | 110−43.6%100% | 195−17.8%100% | 238−4.0%100% | 248−25.7%100% | 334+318%100% | 80—100% | — | |
| Accounts payable | 1.8−30.3%2.7% | 2.6−47.5%2.3% | 4.9−26.6%2.5% | 6.7+49.7%2.8% | 4.4r4.4−22.0%1.8% | 5.7+572%1.7% | 0.8—1.1% | — | |
| Current liabilities | 13−86.4%19.4% | 93+66.7%84.4% | 56+6.1%28.6% | 53+36.6%22.1% | 39−37.8%15.6% | 62+208%18.6% | 20—25.2% | — | |
| Total liabilities | 17−89.4%25.9% | 159−27.3%144% | 219−6.8%112% | 234+36.7%98.5% | 171−20.5%69.2% | 216+423%64.6% | 41—51.7% | — | |
| Retained earnings | −362—−556% | −452—−410% | −413—−211% | −310—−130% | −224—−90.6% | −174—−52.3% | −148—−186% | — | |
| Shareholders' equity | 48—74.1% | −49—−44.1% | −23−748%−11.8% | 3.6−95.4%1.5% | 76−35.3%30.8% | 118—35.4% | −144—−181% | −123—— | |
| Total liabilities and equity | 65−41.0%100% | 110−43.6%100% | 195−17.8%100% | 238−4.0%100% | 248−25.7%100% | 334+318%100% | 80—100% | — | |
| Shares outstanding | 39+1.2%— | 38+3.0%— | 37+23.2%— | 30+0.9%— | 30+1.5%— | 29+2633%— | 1.1r0.0—— | — | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 1.7−1.1%3.8% | 1.7−3.1%4.5% | 1.8+7.4%7.0% | 1.6+14.9%6.3% | 1.4+3.8%3.6% | 1.4−2.1%3.6% | 1.4+19.8%5.7% | 1.2—3.7% | |
| Share-based compensation | 6.8−27.3%15.4% | 9.4−15.4%24.7% | 11+3.4%44.3% | 11+73.8%41.6% | 6.2+257%15.7% | 1.7+108%4.6% | 0.8−1.2%3.4% | 0.8—2.7% | |
| Cash from operating activities | −45—−101% | −85—−223% | −37—−147% | −75—−290% | −84r−85−158%−214% | 145—383% | −33—−135% | −11—−35.9% | |
| Capital expenditure | −0.7—−1.5% | −0.6—−1.5% | −1.2—−4.6% | −1.4—−5.3% | −1.8—−4.6% | −0.6—−1.5% | −0.7—−2.9% | −2.2—−7.2% | |
| Cash from investing activities | 41−28.1%92.7% | 57—150% | −30−136%−118% | 84—323% | −98r−98—−249% | −58−252%−153% | 38+413%154% | 7.4—23.6% | |
| Shares issued | — | — | — | — | — | 21—54.3% | — | — | |
| Dividends paid | — | — | — | — | 0—0.0% | 0—0.0% | — | — | |
| Cash from financing activities | 0.1−97.8%0.2% | 4.0−93.8%10.6% | 65+3564%259% | 1.8−14.6%6.9% | 2.1−98.0%5.3% | 106—280% | −0.2—−0.8% | −0.7—−2.2% | |
| Change in cash | −3.6—−8.1% | −24—−62.1% | −1.5−114%−5.9% | 10—39.8% | −181−194%−457% | 193+4203%510% | 4.5—18.1% | −4.6—−14.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Dec 31, 2018 | Q4 FY2018to Dec 31, 2018 | Q3 FY2018to Sep 30, 2018 | Q2 FY2018to Jun 30, 2018 | Q1 FY2018to Mar 31, 2018 | Q4 FY2017to Dec 31, 2017 | Q3 FY2017to Sep 30, 2017 | Q2 FY2017to Jun 30, 2017 | Q1 FY2017to Mar 31, 2017 | Q4 FY2016to Dec 31, 2016 | Q3 FY2016to Sep 30, 2016 | Q2 FY2016to Jun 30, 2016 | Q1 FY2016to Mar 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 44+16.4%100% | 10−50.7%100% | 20+282%100% | 6.9+10.9%100% | 7.8+26.3%100% | 21+232%100% | 5.1−13.7%100% | 6.2−7.1%100% | 6.2−2.2%100% | 6.2—100% | 5.9—100% | 6.7—100% | 6.4—100% | |
| Research and development | 34−42.4%77.5% | 8.0*−6.9%78.3% | 10−17.8%51.4% | 8.1−46.6%117% | 8.4−65.0%107% | 8.6*−64.6%41.5% | 12−55.4%239% | 15−49.2%244% | 24−15.5%386% | 24*—390% | 27—462% | 30—446% | 28—447% | |
| General and administrative | 18+8.4%40.9% | 5.4*+41.0%52.7% | 3.7−4.4%19.0% | 3.7−9.6%53.9% | 5.4+8.2%68.7% | 3.8*−12.7%18.5% | 3.9−13.8%75.8% | 4.1−14.2%66.1% | 5.0−4.1%80.2% | 4.4*—70.2% | 4.5—75.9% | 4.8—71.6% | 5.2—81.9% | |
| Operating expenses | 54−31.2%123% | 15+22.6%149% | 14−14.9%70.3% | 12−45.6%171% | 14−52.4%176% | 12−56.7%60.1% | 16−49.4%316% | 22−37.3%349% | 29−13.8%466% | 29—460% | 32—538% | 34—517% | 34—529% | |
| Operating income | −10—−22.6% | −5.0*−161%−49.3% | 5.8—29.7% | −4.9—−71.1% | −5.9—−75.6% | 8.2*—39.9% | −11—−216% | −15—−249% | −23—−366% | −22*—−360% | −26—−438% | −28—−417% | −27—−429% | |
| Income before tax | −8.5—−19.1% | −4.7*−156%−45.8% | 6.1—31.3% | −4.4—−63.5% | −5.6—−71.0% | 8.4*—40.5% | −11—−209% | −15—−246% | −23—−364% | −22*—−359% | −26—−437% | −28—−415% | −27—−429% | |
| Income tax | −0.4—−0.9% | 0.0*—0.0% | 0*−100%0.0% | −0.4−9800%−5.6% | 0.0+25.0%0.1% | −1.1*—−5.3% | 0.0−55.6%0.1% | 0.00.0%0.1% | 0.0+33.3%0.1% | −0.0*—−0.0% | 0.0—0.2% | 0.0—0.1% | 0.0—0.0% | |
| Net income including minority interests | — | −4.7*−149%−45.8% | 6.1*—31.3% | — | — | 9.5*—45.8% | −11*—−209% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −8.1—−18.2% | −4.7−149%−45.8% | 6.1—31.3% | −4.0—−57.9% | −5.6—−71.0% | 9.5—45.8% | −11—−209% | −15—−246% | −23—−364% | −22—−359% | −26—−437% | −28—−415% | −27—−429% | |
| Earnings per share, basic | -0.21—— | -0.12−148%— | 0.16—— | -0.10—— | -0.15—— | 0.25—— | -0.28—— | -0.40—— | -0.61—— | -0.60—— | -0.77—— | -0.91—— | -0.90—— | |
| Earnings per share, diluted | -0.21—— | -0.12−148%— | 0.16—— | -0.10—— | -0.15—— | 0.25—— | -0.28—— | -0.40—— | -0.61—— | -0.60—— | -0.77—— | -0.91—— | -0.90—— | |
| Shares, weighted average (basic) | — | — | 39+2.2%— | — | — | — | 38—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | 39+2.3%— | 38+2.0%— | 38+2.6%— | — | 38+11.6%— | 38+24.2%— | 37+23.3%— | — | 34—— | 30—— | 30—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 9.7—14.9% | 9.7−27.0%14.9% | 8.4−47.1%10.9% | 11−66.9%12.3% | 14−64.0%14.8% | 13−64.1%12.0% | 16−47.2%13.2% | 32−15.4%22.9% | 39−53.6%23.5% | 37—18.9% | 30—13.8% | 38—20.8% | 85—41.3% | |
| Short-term investments | 48—73.2% | 48−46.9%73.2% | 62−36.1%80.9% | 69−29.2%80.7% | 74−36.9%78.1% | 90−39.2%81.4% | 98−45.0%81.1% | 98−26.9%70.2% | 118+8.1%70.5% | 148—75.5% | 178—81.4% | 134—73.5% | 109—53.2% | |
| Other current assets | 1.9—2.9% | 1.9+11.9%2.9% | 1.9−21.3%2.5% | 1.5−53.6%1.7% | 1.7−47.9%1.8% | 1.7−31.5%1.5% | 2.4−14.3%2.0% | 3.2+27.1%2.3% | 3.2−10.2%1.9% | 2.5—1.3% | 2.8—1.3% | 2.5—1.4% | 3.6—1.7% | |
| Current assets | 64—97.9% | 64−39.4%97.9% | 73−37.1%94.9% | 81−39.6%94.8% | 90−44.2%95.0% | 105−44.5%95.4% | 116−45.3%96.6% | 135−23.3%96.9% | 162−18.4%96.9% | 190—97.0% | 213—97.5% | 176—96.8% | 198—96.8% | |
| Property, plant and equipment | 0.6—1.0% | 0.6−81.0%1.0% | 2.4−29.9%3.1% | 2.5−33.1%2.9% | 2.9−29.7%3.1% | 3.3−26.8%3.0% | 3.4−22.7%2.8% | 3.8−18.5%2.7% | 4.2−15.0%2.5% | 4.5—2.3% | 4.4—2.0% | 4.6—2.6% | 4.9—2.4% | |
| Total assets | 65—100% | 65−41.0%100% | 77−36.0%100% | 86−38.3%100% | 95−43.0%100% | 110−43.6%100% | 120−44.8%100% | 139−23.4%100% | 167−18.5%100% | 195—100% | 218—100% | 182—100% | 205—100% | |
| Accounts payable | 1.8—2.7% | 1.8−30.3%2.7% | 3.2+306%4.1% | 1.0−53.6%1.1% | 0.7−82.0%0.7% | 2.6−47.5%2.3% | 0.8−85.7%0.6% | 2.1−52.5%1.5% | 3.9+21.7%2.3% | 4.9—2.5% | 5.4—2.5% | 4.5—2.4% | 3.2—1.6% | |
| Current liabilities | 13—19.4% | 13−86.4%19.4% | 21−37.9%27.7% | 33−16.6%38.7% | 35−29.5%36.6% | 93+66.7%84.4% | 34−38.1%28.5% | 40−26.6%28.6% | 49+2.1%29.6% | 56—28.6% | 55—25.4% | 54—29.9% | 48—23.6% | |
| Total liabilities | 17—25.9% | 17−89.4%25.9% | 25−86.1%33.0% | 42−78.3%48.8% | 49−76.5%51.3% | 159−27.3%144% | 183−17.5%152% | 193−14.3%139% | 208−7.6%124% | 219—112% | 221—101% | 225—124% | 225—110% | |
| Retained earnings | −362—−556% | −362—−556% | −357—−463% | −363—−423% | −359—−378% | −452—−410% | −461—−383% | −451—−323% | −436—−261% | −413—−211% | −391—−179% | −365—−201% | −337—−164% | |
| Shareholders' equity | 48—74.1% | 48—74.1% | 52—67.0% | 44—51.2% | 46—48.7% | −49—−44.1% | −62—−51.6% | −54—−38.6% | −41—−24.4% | −23—−11.8% | −3.2—−1.5% | −44—−23.9% | −20—−9.7% | |
| Total liabilities and equity | 65—100% | 65−41.0%100% | 77−36.0%100% | 86−38.3%100% | 95−43.0%100% | 110−43.6%100% | 120−44.8%100% | 139−23.4%100% | 167−18.5%100% | 195—100% | 218—100% | 182—100% | 205—100% | |
| Shares outstanding | 39—— | 39+1.2%— | 39+2.0%— | 38+2.1%— | 38+1.7%— | 38+3.0%— | 38+1.8%— | 38+23.8%— | 38+24.2%— | 37—— | 37—— | 30—— | 30—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.7−1.1%3.8% | 0.4*−5.0%4.0% | 0.4*+2.4%2.2% | 0.4*−0.7%6.3% | 0.4−1.2%5.4% | 0.4*−2.8%2.1% | 0.4*−5.1%8.3% | 0.4*−2.9%7.0% | 0.4−1.4%6.9% | 0.4*—7.0% | 0.4*—7.6% | 0.4*—6.7% | 0.4—6.8% | |
| Share-based compensation | 6.8−27.3%15.4% | 1.1*−46.6%11.2% | 1.6−18.5%8.2% | 1.8−16.8%26.7% | 2.3−27.1%29.0% | 2.1*−9.3%10.3% | 2.0−31.0%38.2% | 2.2−25.4%35.5% | 3.1+4.3%50.3% | 2.4*—37.9% | 2.8—47.8% | 3.0—44.3% | 3.0—47.2% | |
| Cash from operating activities | — | −13*—−132% | −8.8*—−45.2% | — | −14—−183% | −12*—−59.8% | −17*—−324% | −27*—−438% | −29−181%−466% | −23*—−367% | −27*—−459% | −23*—−342% | 36—565% | |
| Capital expenditure | −0.7—−1.5% | −0.1*—−1.3% | −0.2*—−1.2% | −0.1*—−1.6% | −0.2—−2.2% | −0.1*—−0.5% | −0.0*—−0.4% | −0.1*—−1.0% | −0.4—−6.4% | −0.3*—−4.8% | −0.2*—−2.7% | −0.2*—−2.7% | −0.5—−8.1% | |
| Cash from investing activities | — | 15*+85.8%144% | 6.6*+330450%33.9% | — | 15−48.4%194% | 7.9*−73.3%38.3% | 0.0*—0.0% | 20*—320% | 29+211%475% | 30*—477% | −44*—−741% | −25*—−375% | 9.5—150% | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | 63*—1064% | — | — | |
| Cash from financing activities | — | 0*−100%0.0% | 0.0*−89.9%0.2% | — | 0.0−97.6%0.5% | 1.8*+2821%8.9% | 0.5*−99.3%9.1% | 0.0*−99.5%0.1% | 1.7+134%27.9% | 0.1*—1.0% | 63*—1071% | 1.0*—14.7% | 0.7—11.7% | |
| Change in cash | −3.6—−8.1% | 1.3*—12.6% | −2.2*—−11.0% | −3.6*—−51.9% | 0.8−62.2%10.8% | −2.6*−138%−12.6% | −16*—−315% | −7.3*—−117% | 2.2−95.1%36.1% | 6.9*—110% | −7.7*—−130% | −47*—−702% | 46—726% | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2018. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at OncoMed#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Delisting notice 1 · Restructuring 2 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 2 · Agreement ended 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| RestructuringDirectors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Apr 23, 2019
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2013 | $22 M | No. 1 | $10 to $50 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | · | · | · | · | · | · | · | · | · | · | · | 39 | 39 |
| 2017 | · | · | · | 60 | · | · | · | · | · | · | · | · | 60 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 39 people | Restructuring planSEC 8-K | “In connection with the proposed Merger disclosed in Item 1.01 above, on December 4, 2018, the Board of Directors of the Company (the “Company Board”) approved a reduction to the Co…” | Filing | |
| 60 people | Restructuring planSEC 8-K | “Under this plan, the Company plans to reduce its workforce by 60 employees (or 48%) to 64 employees.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How OncoMed compares in Biotechnology
- Revenue$44 M · higher than 58% of 647
- Net margin-18.2% · higher than 62% of 408
- Revenue growth16.4% · higher than 59% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| OncoMed🇺🇸 | — | — | -18.2% | +16.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2018
- Balance sheet:
- As of December-2018
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at OncoMed? Verify and update this profile — free
Show OncoMed's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.